Biomea Fusion, Inc. Common Stock
BMEABiomea Fusion, Inc. (BMEA) is a biopharmaceutical company focused on developing targeted therapies for cancer and rare diseases. The company aims to leverage its precision medicine platform to identify and advance novel drug candidates with the potential to address unmet medical needs in oncology and other therapeutic areas.
Company News
Biomea Fusion presented clinical and translational data for icovamenib at the ADA 86th Scientific Sessions, demonstrating improvements in HbA1c and C-peptide levels in type 1 and type 2 diabetes patients, along with potential benefits for muscle preservation and fat reduction. The company also expanded its Phase I BMF-650 study to evaluate rapid ...
Biomea Fusion reported Q1 2026 net loss of $12.4 million, down significantly from $29.3 million in Q1 2025, driven by reduced R&D and G&A expenses following headcount reductions. The company announced positive 52-week data from its Phase II COVALENT-112 trial showing icovamenib achieved a 52% increase in C-peptide levels in recently diagnosed typ...
Biomea Fusion announced that three abstracts on icovamenib, its investigational oral menin inhibitor, have been selected for late-breaking poster presentations at the ADA 86th Scientific Sessions in June 2026. The presentations will showcase data from Phase 2 trials (COVALENT-111 and COVALENT-112) demonstrating icovamenib's potential to improve b...
Biomea Fusion announced the first patient dosing in two Phase II clinical trials (COVALENT-211 and COVALENT-212) evaluating icovamenib for type 2 diabetes patients failing standard-of-care therapies. COVALENT-211 targets insulin-deficient T2D patients, while COVALENT-212 targets patients uncontrolled on GLP-1 receptor agonists. Both studies will ...
Biomea Fusion announced positive 52-week follow-up results from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes patients. The drug demonstrated durable efficacy nine months post-dosing, with severe insulin-deficient diabetes patients achieving a 1.2% HbA1c reduction at Week 52. The company maintained a favorable safety profile an...
